Nanobody-functionalized Polymersomes for Tumor-vessel Targeting
Overview
Biology
Authors
Affiliations
Targeted carrier systems (e.g., liposomes or nanoparticles) are used to specifically deliver drugs to a site of interest. Site-direction can be achieved by attachment of targeting molecules, such as peptides, DNA/RNA, or antibodies, to the surface of the carrier. Here, the formation of polymersomes with tumor-targeting potential is described. A single-domain antibody (A12) that specifically targets PlexinD1 (a transmembrane protein overexpressed in tumor vasculature) is equipped with an azide-functionality using expressed protein ligation. This azide-containing A12 can subsequently be attached to BCN-functionalized polymersomes using a strain-promoted azide alkyne cycloaddition, thereby forming polymersomes with tumor-targeting potential.
Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines.
Maksymova L, Pilger Y, Nuhn L, Van Ginderachter J Mol Cancer. 2025; 24(1):65.
PMID: 40033293 PMC: 11877942. DOI: 10.1186/s12943-025-02270-5.
Nanobodies Outperform Antibodies - Rapid Functionalization with Equal In Vivo Targeting Properties.
Jung C, Fichter M, Oberlander J, Schunke J, Bolduan V, Schneider P Adv Mater. 2024; 36(52):e2412563.
PMID: 39468885 PMC: 11681313. DOI: 10.1002/adma.202412563.
Single-domain antibodies as therapeutics for solid tumor treatment.
Wang M, Ying T, Wu Y Acta Pharm Sin B. 2024; 14(7):2854-2868.
PMID: 39027249 PMC: 11252471. DOI: 10.1016/j.apsb.2024.03.016.
Plexin D1 mediates disturbed flow-induced M1 macrophage polarization in atherosclerosis.
Zhang S, Zhang Y, Zhang P, Wei Z, Ma M, Wang W Heliyon. 2023; 9(6):e17314.
PMID: 37389065 PMC: 10300222. DOI: 10.1016/j.heliyon.2023.e17314.
Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy.
Sun S, Ding Z, Yang X, Zhao X, Zhao M, Gao L Int J Nanomedicine. 2021; 16:2337-2356.
PMID: 33790553 PMC: 7997558. DOI: 10.2147/IJN.S297631.